Drugs / 18F-AzaFol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03242993 | Apr 2017 → Jun 2019 | lung cancer, ovarian cancer | University of Lausanne Hospitals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-AzaFol | “18F-AzaFol (3'-aza-2'-[18F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.” PMID 32270313 ↗ Apr 2020 |
| Known as | 3'-aza-2'-[18F]fluorofolic acid | “18F-AzaFol (3'-aza-2'-[18F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.” PMID 32270313 ↗ Apr 2020 |
| Modality | Diagnostic / imaging agent | “18F-AzaFol (3'-aza-2'-[18F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.” PMID 32270313 ↗ Apr 2020 |
| Route | Intravenous | “after the intravenous injection of 327 MBq (range 299-399 MBq) of 18F-AzaFol” PMID 32270313 ↗ Apr 2020 |